Literature DB >> 29273331

Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease.

Alejandro R Chade1, Maxx L Williams2, Erika Guise2, Luke J Vincent2, Taylor W Harvey2, Marija Kuna3, Fakhri Mahdi4, Gene L Bidwell5.   

Abstract

We recently developed a therapeutic biopolymer composed of an elastin-like polypeptide (ELP) fused to vascular endothelial growth factor (VEGF) and showed long-term renoprotective effects in experimental renovascular disease after a single intra-renal administration. Here, we sought to determine the specificity, safety, efficacy, and mechanisms of renoprotection of ELP-VEGF after systemic therapy in renovascular disease. We tested whether kidney selectivity of the ELP carrier would reduce off-target binding of VEGF in other organs. In vivo bio-distribution after systemic administration of ELP-VEGF in swine was determined in kidneys, liver, spleen, and heart. Stenotic-kidney renal blood flow and glomerular filtration rate were quantified in vivo using multi-detector computed tomography (CT) after six weeks of renovascular disease, then treated with a single intravenous dose of ELP-VEGF or placebo and observed for four weeks. CT studies were then repeated and the pigs euthanized. Ex vivo studies quantified renal microvascular density (micro-CT) and fibrosis. Kidneys, liver, spleen, and heart were excised to quantify the expression of angiogenic mediators and markers of progenitor cells. ELP-VEGF accumulated predominantly in the kidney and stimulated renal blood flow, glomerular filtration rate, improved cortical microvascular density, and renal fibrosis, and was accompanied by enhanced renal expression of VEGF, downstream mediators of VEGF signaling, and markers of progenitor cells compared to placebo. Expression of angiogenic factors in liver, spleen, and heart were not different compared to placebo-control. Thus, ELP efficiently directs VEGF to the kidney after systemic administration and induces long-term renoprotection without off-target effects, supporting the feasibility and safety of renal therapeutic angiogenesis via systemic administration of a novel kidney-specific bioengineered compound.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  drug delivery; elastin-like polypeptide; imaging; renal hemodynamics; renal injury; renovascular disease; vascular endothelial growth factor

Mesh:

Substances:

Year:  2017        PMID: 29273331      PMCID: PMC5866753          DOI: 10.1016/j.kint.2017.09.029

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  43 in total

1.  The renal papilla is a niche for adult kidney stem cells.

Authors:  Juan A Oliver; Omar Maarouf; Faisal H Cheema; Timothy P Martens; Qais Al-Awqati
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

2.  Combination of hypercholesterolemia and hypertension augments renal function abnormalities.

Authors:  M Rodriguez-Porcel; J D Krier; A Lerman; P F Sheedy; J C Romero; C Napoli; L O Lerman
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

3.  Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney.

Authors:  Henrik Dimke; Matthew A Sparks; Benjamin R Thomson; Sebastian Frische; Thomas M Coffman; Susan E Quaggin
Journal:  J Am Soc Nephrol       Date:  2014-11-10       Impact factor: 10.121

4.  High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization.

Authors:  James Ritchie; Darren Green; Constantina Chrysochou; Nicholas Chalmers; Robert N Foley; Philip A Kalra
Journal:  Am J Kidney Dis       Date:  2013-09-26       Impact factor: 8.860

Review 5.  The SDF-1/CXCR4 axis in stem cell preconditioning.

Authors:  Chiara Cencioni; Maurizio C Capogrossi; Monica Napolitano
Journal:  Cardiovasc Res       Date:  2012-03-26       Impact factor: 10.787

Review 6.  Human endothelial progenitor cells.

Authors:  Mervin C Yoder
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

7.  Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant-kidney model.

Authors:  H Kitamura; A Shimizu; Y Masuda; M Ishizaki; Y Sugisaki; N Yamanaka
Journal:  Exp Nephrol       Date:  1998 Jul-Aug

8.  Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress.

Authors:  Xiang-Yang Zhu; Alejandro R Chade; Martin Rodriguez-Porcel; Michael D Bentley; Erik L Ritman; Amir Lerman; Lilach O Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-12       Impact factor: 8.311

9.  Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells.

Authors:  Takeshi Kubota; Atsushi Matsumura; Hiroaki Taiyoh; Yasuhito Izumiya; Hitoshi Fujiwara; Kazuma Okamoto; Daisuke Ichikawa; Atsushi Shiozaki; Shuhei Komatsu; Masayoshi Nakanishi; Yoshiaki Kuriu; Yasutoshi Murayama; Hisashi Ikoma; Toshiya Ochiai; Takahiro Nakamura; Kunio Matsumoto; Toshikazu Nakamura; Eigo Otsuji
Journal:  Oncol Rep       Date:  2013-05-29       Impact factor: 3.906

10.  Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct.

Authors:  Alejandro R Chade; Nathan A Tullos; Taylor W Harvey; Fakhri Mahdi; Gene L Bidwell
Journal:  J Am Soc Nephrol       Date:  2015-11-05       Impact factor: 10.121

View more
  20 in total

Review 1.  Novel therapeutic strategies for renovascular disease.

Authors:  Alfonso Eirin; Stephen C Textor; Lilach O Lerman
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

2.  Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization.

Authors:  Erika Guise; Jason E Engel; Maxx L Williams; Fakhri Mahdi; Gene L Bidwell; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-20

3.  Recovery of Renal Function following Kidney-Specific VEGF Therapy in Experimental Renovascular Disease.

Authors:  Jason E Engel; Maxx L Williams; Erika Williams; Camille Azar; Erin B Taylor; Gene L Bidwell; Alejandro R Chade
Journal:  Am J Nephrol       Date:  2020-10-30       Impact factor: 3.754

Review 4.  VEGF therapy for the kidney: emerging strategies.

Authors:  Erika Guise; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2018-02-14

5.  Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform.

Authors:  Gene L Bidwell
Journal:  Physiology (Bethesda)       Date:  2021-09-06

Review 6.  Targeting angiogenesis and lymphangiogenesis in kidney disease.

Authors:  Katsuyuki Tanabe; Jun Wada; Yasufumi Sato
Journal:  Nat Rev Nephrol       Date:  2020-03-06       Impact factor: 28.314

7.  Molecular targeting of renal inflammation using drug delivery technology to inhibit NF-κB improves renal recovery in chronic kidney disease.

Authors:  Alejandro R Chade; Maxx L Williams; Jason E Engel; Erika Williams; Gene L Bidwell
Journal:  Am J Physiol Renal Physiol       Date:  2020-06-15

8.  A translational model of chronic kidney disease in swine.

Authors:  Alejandro R Chade; Maxx L Williams; Jason Engel; Erika Guise; Taylor W Harvey
Journal:  Am J Physiol Renal Physiol       Date:  2018-04-25

Review 9.  Inflammation and Oxidative Damage in Ischaemic Renal Disease.

Authors:  Áine M de Bhailís; Constantina Chrysochou; Philip A Kalra
Journal:  Antioxidants (Basel)       Date:  2021-05-25

10.  Targeted VEGF (Vascular Endothelial Growth Factor) Therapy Induces Long-Term Renal Recovery in Chronic Kidney Disease via Macrophage Polarization.

Authors:  Jason E Engel; Erika Williams; Maxx L Williams; Gene L Bidwell; Alejandro R Chade
Journal:  Hypertension       Date:  2019-09-23       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.